drugset / Trial / NCT02060552

Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels

NCT02060552

Phase 4 Completed 96 enrolled Tongji Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of study was to assess the efficiency and safety of oral IL-1βinhibitor in combination with urate lowering therapy on joint pain intensity,urate control, global assessments of disease activity, self-monitored gouty acute flare times, inflammatory markers and symptoms improving related life quantity in gouty patients.

Timeline

Start
2013-01
Primary completion
2014-03
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Colchicine Small molecule 0.5 mg
Subject Diacerein Small molecule 50 mg Oral
Background Febuxostat Small molecule 40 mg

Indications